Your browser doesn't support javascript.
loading
High-throughput Phenotyping of Lung Cancer Somatic Mutations.
Berger, Alice H; Brooks, Angela N; Wu, Xiaoyun; Shrestha, Yashaswi; Chouinard, Candace; Piccioni, Federica; Bagul, Mukta; Kamburov, Atanas; Imielinski, Marcin; Hogstrom, Larson; Zhu, Cong; Yang, Xiaoping; Pantel, Sasha; Sakai, Ryo; Watson, Jacqueline; Kaplan, Nathan; Campbell, Joshua D; Singh, Shantanu; Root, David E; Narayan, Rajiv; Natoli, Ted; Lahr, David L; Tirosh, Itay; Tamayo, Pablo; Getz, Gad; Wong, Bang; Doench, John; Subramanian, Aravind; Golub, Todd R; Meyerson, Matthew; Boehm, Jesse S.
Afiliação
  • Berger AH; Dana-Farber Cancer Institute, Boston, MA.
  • Brooks AN; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Wu X; Harvard Medical School, Boston, MA.
  • Shrestha Y; Dana-Farber Cancer Institute, Boston, MA.
  • Chouinard C; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Piccioni F; Harvard Medical School, Boston, MA.
  • Bagul M; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Kamburov A; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Imielinski M; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Hogstrom L; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Zhu C; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Yang X; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Pantel S; Harvard Medical School, Boston, MA.
  • Sakai R; Department of Pathology and Cancer Center, Massachusetts General Hospital, Boston, MA.
  • Watson J; Dana-Farber Cancer Institute, Boston, MA.
  • Kaplan N; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Campbell JD; Harvard Medical School, Boston, MA.
  • Singh S; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Root DE; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Narayan R; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Natoli T; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Lahr DL; KU Leuven, Leuven, Belgium.
  • Tirosh I; Dana-Farber Cancer Institute, Boston, MA.
  • Tamayo P; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Getz G; Dana-Farber Cancer Institute, Boston, MA.
  • Wong B; Dana-Farber Cancer Institute, Boston, MA.
  • Doench J; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Subramanian A; Harvard Medical School, Boston, MA.
  • Golub TR; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Meyerson M; Broad Institute of MIT and Harvard, Cambridge, MA.
  • Boehm JS; Broad Institute of MIT and Harvard, Cambridge, MA.
Cancer Cell ; 30(2): 214-228, 2016 08 08.
Article em En | MEDLINE | ID: mdl-27478040
ABSTRACT
Recent genome sequencing efforts have identified millions of somatic mutations in cancer. However, the functional impact of most variants is poorly understood. Here we characterize 194 somatic mutations identified in primary lung adenocarcinomas. We present an expression-based variant-impact phenotyping (eVIP) method that uses gene expression changes to distinguish impactful from neutral somatic mutations. eVIP identified 69% of mutations analyzed as impactful and 31% as functionally neutral. A subset of the impactful mutations induces xenograft tumor formation in mice and/or confers resistance to cellular EGFR inhibition. Among these impactful variants are rare somatic, clinically actionable variants including EGFR S645C, ARAF S214C and S214F, ERBB2 S418T, and multiple BRAF variants, demonstrating that rare mutations can be functionally important in cancer.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Sequenciamento de Nucleotídeos em Larga Escala / Neoplasias Pulmonares / Mutação Limite: Animals / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Sequenciamento de Nucleotídeos em Larga Escala / Neoplasias Pulmonares / Mutação Limite: Animals / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article